Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Latanoprost
Drug ID BADD_D01251
Description Latanoprost is a prodrug analog of prostaglandin F2 alpha that is used to treat elevated intraocular pressure (IOP). It was initially approved by the FDA in 1998. Latanoprost is the first topical prostaglandin F2 alpha analog used for glaucoma treatment.[A184493] It has been found to be well-tolerated and its use does not normally result in systemic adverse effects like other drugs used to treat elevated intraocular pressure, such as [Timolol]. Another benefit latanoprost is that it can be administered once a day.[A184490]
Indications and Usage For the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Marketing Status Prescription; Discontinued
ATC Code S01EE01
DrugBank ID DB00654
KEGG ID D00356
MeSH ID D000077338
PubChem ID 5311221
TTD Drug ID D0C6NM
NDC Product Code 90027-006; 68071-2376; 59762-0333; 47335-317; 24208-463; 63190-0710; 65326-004; 45542-1156; 0009-5172; 51927-4864; 42385-039; 55545-0462; 71684-0547; 45542-1159; 68071-4893; 12079-0475; 64980-516; 50090-1920; 61314-547; 51927-0091; 68245-0002; 71205-154; 65035-128; 51552-1385; 17478-625; 46144-156; 65862-872; 40016-001; 71052-041; 61919-112; 65727-026; 61556-050; 65427-007; 81997-001; 68071-4650; 51927-0090; 24002-0018; 54893-0010; 10695-048; 0013-8303; 82231-111; 68071-4612; 70069-421
Synonyms Latanoprost | PhXA34 | PHXA41 | Xalatan
Chemical Information
Molecular Formula C26H40O5
CAS Registry Number 130209-82-4
SMILES CC(C)OC(=O)CCCC=CCC1C(CC(C1CCC(CCC2=CC=CC=C2)O)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Anaphylactoid shock24.06.02.005; 10.01.07.0040.000225%Not Available
Metamorphopsia17.17.01.020; 06.02.06.0140.000675%Not Available
Dark circles under eyes08.01.03.054; 06.08.03.0190.000225%Not Available
Ulcerative keratitis06.04.02.004; 10.02.01.0210.000338%
Treatment failure08.06.01.0170.000147%Not Available
Ocular surface disease06.08.03.0160.000338%Not Available
Oropharyngeal pain22.02.05.022; 07.05.05.0040.001013%
Ophthalmic herpes simplex11.05.02.017; 06.04.05.0190.000450%Not Available
Medication residue present13.15.01.0320.000225%Not Available
Reading disorder19.21.05.0030.000225%Not Available
Senile dementia19.20.02.009; 17.03.01.0080.000059%Not Available
Superficial injury of eye12.01.04.032; 06.11.04.0010.000225%Not Available
Symblepharon06.06.02.0120.000225%Not Available
Intraocular pressure test abnormal13.07.04.0070.000338%Not Available
Keratitis bacterial11.02.01.006; 06.04.02.0050.000225%Not Available
Toxic anterior segment syndrome12.02.02.010; 06.04.10.0060.000225%Not Available
Quality of life decreased13.18.01.0130.000225%Not Available
Ocular pemphigoid23.03.01.030; 10.04.04.015; 06.04.05.0300.000450%Not Available
Intraocular pressure fluctuation13.07.04.0150.000338%Not Available
Nail injury23.02.05.025; 12.01.06.0140.000225%Not Available
Eye colour change06.06.06.0080.000563%Not Available
The 10th Page    First    Pre   10    Total 10 Pages